Clinical trial
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With…
NCT03112603 · Incyte Corporation, Industry · Completed
Key facts
| NCT number | NCT03112603 |
|---|---|
| Title | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) |
| Official title | A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3) |
| Lead sponsor | Incyte Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft-versus-host Disease (GVHD) |
| Intervention type | Drug |
| Interventions | Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib |
| Enrollment | 330 |
| Start date | Jun 29, 2017 |
| Primary completion | May 8, 2020 |
| Completion | Dec 15, 2022 |
| First posted | Apr 13, 2017 |
| Last update posted | Aug 12, 2025 |
| Countries | Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India and 19 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: